BriaCell Partners with Receptor.AI to Develop AI-Driven Cancer Kinase Inhibitors
核心洞察
BriaCell's subsidiary BriaPro has initiated a research collaboration with Receptor.AI (搜索) to design anti-cancer isoform-selective kinase inhibitors for multiple cancer indications.
The partnership integrates AI-driven molecular design expertise with BriaPro's proprietary technology to expand the small-molecule pipeline and accelerate development of selective kinase inhibitors.
Receptor.AI (搜索) will utilize its small-molecule discovery platform to drive target assessment, hit identification, and lead optimization with focus on achieving precise isoform selectivity among closely related kinases.
BriaCell Therapeutics Corp. (搜索) has announced that its subsidiary BriaPro Therapeutics Corp. (搜索) has initiated a research collaboration with Receptor.AI (搜索), an AI-driven drug discovery company, to design anti-cancer isoform-selective kinase inhibitors for multiple cancer indications. The partnership aims to accelerate the development of next-generation therapeutics with improved efficacy and safety.
Strategic Expansion into Small-Molecule Discovery
The collaboration marks a significant strategic shift for BriaCell, expanding beyond its traditional cell-based immunotherapy focus. "This partnership marks an important step in BriaCell's strategic expansion beyond cell-based immunotherapy into small-molecule discovery, reinforcing its mission to deliver differentiated and complementary approaches to cancer treatment," stated Dr. William V. Williams, President and CEO of BriaCell and BriaPro.
The partnership will integrate AI-driven molecular design expertise with BriaPro's proprietary technology to expand BriaPro's small-molecule pipeline and accelerate the development of selective kinase inhibitors that may enhance immune-mediated tumor targeting and improve cancer patient outcomes.
Addressing Kinase Selectivity Challenges
The collaboration specifically targets one of oncology's most challenging optimization problems. "Kinase selectivity, down to the isoform level, remains one of the hardest optimization problems in oncology," said Dr. Alan Nafiev, CEO and Founder of Receptor.AI (搜索). "This collaboration is about bringing disciplined, AI-first molecular design and rigorous ADMET constraints to BriaCell's oncology programs, enhancing precision and translational confidence from the earliest stages of discovery."
AI-Driven Drug Discovery Platform
Receptor.AI (搜索) has developed a multiplatform ecosystem for AI-enabled drug discovery, integrating small-molecule, peptide, and induced-proximity technologies into a unified framework that accelerates therapeutic innovation across modalities. Within the collaboration, Receptor.AI will harness its small-molecule discovery platform to drive target assessment, hit identification, and lead optimization, with a particular focus on achieving precise isoform selectivity among closely related kinases.
The AI-driven drug discovery company brings a validated track record across more than 40 discovery programs, integrating machine learning, physics-based modeling, and automated decision-making into a unified R&D platform. Receptor.AI (搜索) drives innovation across small molecules, peptides, and induced-proximity therapeutics, partnering with global biopharma and academic institutions to unlock challenging targets and accelerate the path from concept to clinic.
Company Profiles
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. BriaPro Therapeutics Corp. (搜索) is a pre-clinical stage immunotherapy company developing binding agents and proteins designed to enhance the ability of the body's own cancer-fighting cells to eliminate tumors. BriaPro is a wholly owned subsidiary of BriaCell Therapeutics Corp. (搜索)